Download PDF
Aktuelle Dermatologie 2019; 45(01/02): 32-39
DOI: 10.1055/a-0806-9034
Eine Klinik im Blickpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Pityriasis rubra pilaris – eine seltene entzündliche Dermatose mit vielen Facetten

Pityriasis rubra pilaris – A Rare Multifacetted Inflammatory Skin Disease
K. Kahlert
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
,
H. Hamm
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
,
M. Goebeler
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
,
A. Kerstan
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
› Author Affiliations
Further Information

Publication History

Publication Date:
12 February 2019 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die Pityriasis rubra pilaris (PRP) ist eine seltene entzündliche, papulosquamöse Dermatose, die in 6 verschiedenen Manifestationsformen (Subtypen) sowohl bei Kindern als auch bei Erwachsenen mit großer Variabilität auftreten kann. Bei allen Subtypen sind in den Anfangsstadien follikulär gebundene, keratotische Papeln zu beobachten, die nach variabler Latenz zu unterschiedlich großen, gut begrenzten Plaques mit krankheitstypischem, orange-rotem Farbton konfluieren. Dabei finden sich bei den ausgedehnteren Verlaufsformen charakteristischerweise innerhalb der Plaques Inseln gesunder Haut (nappes claires). Nicht selten entsteht eine palmare und plantare, wechselnd stark ausgeprägte Hyperkeratose. Die PRP bietet ein breites klinisches Spektrum, das von einem lokalisierten Befall der Extremitäten bis hin zu erythrodermatischen Formen reicht, die mitunter bereits im Säuglingsalter beginnen können.

Die vorliegende Arbeit gibt eine Übersicht über den aktuellen Kenntnisstand dieser bislang wenig verstandenen Dermatose.

Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease. There are 6 distinct subtypes with striking clinical variation in both children and adults. Basic elements noted across all subtypes include follicular keratotic papules that evolve to distinct, well-demarcated, scaling plaques of various sizes with typical reddish-orange hue. More generalized subtypes tend to show intervening areas of unaffected skin, known as “islands of sparing” (nappes claires), which represent a characteristic feature. PRP shows a broad spectrum of presentations ranging from mild manifestations confined to extremities to severe disease developing into erythroderma.

The present review provides an overview of the current state of knowledge of this hitherto poorly understood dermatosis.

 

  • Literatur

  • 1 Rayer PFO. Traite theorique et pratique des maladies de la peau. Libraire de l’Ácadémie de médecine, Paris 1835; 2: 158-159
    PubMedGoogle Scholar
  • 2 Devergie MAG. Pityriasis pilaris, maladie de la peau non decrite par les dermatologistes. Gazette Hebdomedaire de Medecine et de Chirurgie, Paris 1856; 3: 197-201
    PubMedGoogle Scholar
  • 3 Besnier E. Observations pour servir a l’histoire clinique du Pityriasis rubra pilaire. Annales de dermatologie et de syphiligraphie 1889; 10: 253-287
    PubMedGoogle Scholar
  • 4 Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5: 105-112
    CrossrefPubMedGoogle Scholar
  • 5 Ross NA, Chung HJ, Li Q. et al. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients. JAMA Dermatol 2016; 152: 670-675
    CrossrefPubMedGoogle Scholar
  • 6 Finzi AF, Altomare G, Bergamaschini L. et al. Pityriasis rubra pilaris and and retinol-binding protein. Br J Dermatol 1981; 104: 253-256
    CrossrefPubMedGoogle Scholar
  • 7 van Voorst Vader PC, van Oostveen F, Houthoff HJ. et al. Pityriasis rubra pilaris, vitamin A and retinol-binding protein: a case study. Acta Derm Venereol 1984; 64: 430-432
    PubMedGoogle Scholar
  • 8 Stoll DM, King Jr LE, Chytil F. Serum levels of retinol binding protein in patients with pityriasis rubra pilaris. Br J Dermatol 1983; 108: 375
    PubMedGoogle Scholar
  • 9 Zhang YH, Zhou Y, Ball N. et al. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg 2010; 14: 185-188
    CrossrefPubMedGoogle Scholar
  • 10 Feldmeyer L, Mylonas A, Demaria O. et al. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatol 2017; 153: 304-308
    PubMedGoogle Scholar
  • 11 Martin KL, Holland KE, Lyon V. et al. An unusual cluster of circumscribed juvenile pityriasis rubra pilaris cases. Pediatr Dermatol 2014; 31: 138-145
    CrossrefPubMedGoogle Scholar
  • 12 Wang T, Liu J, Liu Y. et al. Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: a new type PRP with non-HIV virus infection?. Chin Med J (Engl) 2014; 127: 2391
    PubMedGoogle Scholar
  • 13 Kawara S, Miyake M, Oiso N. et al. Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology 2009; 219: 350-352
    CrossrefPubMedGoogle Scholar
  • 14 Miralles ES, Nunez M, De Las Heras ME. et al. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995; 133: 990-993
    CrossrefPubMedGoogle Scholar
  • 15 Remedios IM, Jensen JD, Beckum K. et al. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma. J Drugs Dermatol 2014; 13: 610-612
    PubMedGoogle Scholar
  • 16 Kurzydlo AM, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol 2004; 45: 130-132
    CrossrefPubMedGoogle Scholar
  • 17 Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. Dermatology 1997; 194: 166-167
    CrossrefPubMedGoogle Scholar
  • 18 Badri T, Zaouak A, Lakhoua G. et al. Pityriasis rubra pilaris-like eruption following insulin therapy initiation. Dermatol Pract Concept 2016; 6: 19-21
    PubMedGoogle Scholar
  • 19 Franzotti AM, Avelar JC, Cardoso TA. et al. Pityriasis Rubra Pilar and hypothyroidism. An Bras Dermatol 2014; 89: 497-500
    CrossrefPubMedGoogle Scholar
  • 20 Orlandini V, Cogrel O, Doutre MS. et al. Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. Br J Dermatol 2007; 156: 606-607
    CrossrefPubMedGoogle Scholar
  • 21 Sonnex TS, Dawber RP, Zachary CB. et al. The nails in adult type 1 pityriasis rubra pilaris. A comparison with Sézary syndrome and psoriasis. J Am Acad Dermatol 1986; 15: 956-960
    CrossrefPubMedGoogle Scholar
  • 22 MacGillivray ME, Fiorillo L. Recurrent Pityriasis Rubra Pilaris: A Case Report. J Cutan Med Surg 2018; 22: 624-626
    CrossrefPubMedGoogle Scholar
  • 23 De Beurmann B. Heyer. Pityriasis rubra pilaire familial. Nn Dermatol Syphiligr; Paris: 1910 I. 609-619
    PubMedGoogle Scholar
  • 24 Vanderhooft SL, Francis JS, Holbrook KA. et al. Familial pityriasis rubra pilaris. Arch Dermatol 1995; 131: 448-453
    CrossrefPubMedGoogle Scholar
  • 25 Mercer JM, Pushpanthan C, Anandakrishnan C. et al. Familial pityriasis rubra pilaris: case report and review. J Cutaneous Med Surg 2013; 17: 226-232
    PubMedGoogle Scholar
  • 26 Thomson MA, Moss C. Pityriasis rubra pilaris in a mother and two daughters. Br J Dermatol 2007; 157: 202-204
    CrossrefPubMedGoogle Scholar
  • 27 Fuchs-Telem D, Sarig O, van Steensel MA. et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012; 91: 163-170
    CrossrefPubMedGoogle Scholar
  • 28 Eytan O, Qiaoli L, Nousbeck J. et al. Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris. Br J Dermatol 2014; 170: 1196-1198
    CrossrefPubMedGoogle Scholar
  • 29 Hong JB, Chen PL, Chen YT. et al. Genetic analysis of CARD14 in non-familial pityriasis rubra pilaris: a case series. Acta Derm Venereol 2014; 94: 587-588
    PubMedGoogle Scholar
  • 30 Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol 2014; 134: 1755-1757
    CrossrefPubMedGoogle Scholar
  • 31 Berki DM, Liu L, Choon SE. et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol 2015; 135: 2964-2970
    CrossrefPubMedGoogle Scholar
  • 32 Jordan CT, Cao L, Roberson ED. et al. PSORS2 is due to mutations in CARD14. Am J Hum Gen 2012; 90: 784-795
    CrossrefPubMedGoogle Scholar
  • 33 Blasdale C, Turner RJ, Leonard N. et al. Spontaneous clinical improvement in HIV-associated follicular syndrome. Clin Exp Dermatol 2004; 29: 480-482
    CrossrefPubMedGoogle Scholar
  • 34 Gonzalez-Lopez A, Velasco E, Pozo T. et al. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol 1999; 140: 931-934
    CrossrefPubMedGoogle Scholar
  • 35 Soeprono FF. Histologic criteria for the diagnosis of pityriasis rubra pilaris. Am J Dermatopathol 1986; 8: 277-283
    CrossrefPubMedGoogle Scholar
  • 36 Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol 1997; 24: 416-424
    CrossrefPubMedGoogle Scholar
  • 37 Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol 2008; 25: 125-126
    CrossrefPubMedGoogle Scholar
  • 38 Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994; 130: 675-678
    CrossrefPubMedGoogle Scholar
  • 39 Mota F, Carvalho S, Sanches M. et al. Late onset pityriasis rubra pilaris type IV treated with low-dose acitretin. Acta Dermatovenerol Alp Pannonica Adriat 2016; 25: 15-17
    PubMedGoogle Scholar
  • 40 Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 1994; 31: 997-999
    CrossrefPubMedGoogle Scholar
  • 41 Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol 1982; 6: 710-715
    CrossrefPubMedGoogle Scholar
  • 42 Allison DS, El-Azhary RA, Calobrisi SD. et al. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002; 47: 386-389
    CrossrefPubMedGoogle Scholar
  • 43 Moretta G, De Luca EV, Di Stefani A. Management of refractory pityriasis rubra pilaris: challenges and solutions. Clin Cosmet Investig Dermatol 2017; 10: 451-457
    CrossrefPubMedGoogle Scholar
  • 44 Amann PM, Susic M, Gluder F. et al. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol 2015; 95: 329-331
    PubMedGoogle Scholar
  • 45 Boyd AH, Polcari IC. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris. Pediatr Dermatol 2018; 35: e62-e63
    CrossrefPubMedGoogle Scholar
  • 46 Koch L, Schoffl C, Aberer W. et al. Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review. Acta Derm Venereol 2018; 98: 501-505
    PubMedGoogle Scholar
  • 47 Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature. J Am Acad Dermatol 2018; 79: 353-359.e11
    CrossrefPubMedGoogle Scholar
  • 48 Bravo EA, Carrion L, Paucar SM. et al. Successful treatment of pityriasis rubra pilaris with adalimumab – case report. Dermatol Online J 2014; 20: 22374
    PubMedGoogle Scholar
  • 49 Wassef C, Lombardi A, Rao BK. Adalimumab for the treatment of pityriasis rubra pilaris: a case report. Cutis 2012; 90: 244-247
    PubMedGoogle Scholar
  • 50 Aragon-Miguel R, Prieto-Barrios M, Calleja-Algarra A. et al. Therapierefraktäre Pityriasis rubra pilaris mit gutem Ansprechen auf Ustekinumab. J Dtsch Dermatol Ges 2018; 16: 1022-1025
    PubMedGoogle Scholar
  • 51 Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis 2018; 101: 367-369
    PubMedGoogle Scholar
  • 52 Gauci ML, Jachiet M, Gottlieb J. et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep 2016; 2: 462-464
    PubMedGoogle Scholar
  • 53 Schuster D, Pfister-Wartha A, Bruckner-Tuderman L. et al. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol 2016; 152: 1278-1280
    CrossrefPubMedGoogle Scholar
  • 54 Schram ME, Borgonjen RJ, Bik CM. et al. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011; 147: 474-488
    CrossrefPubMedGoogle Scholar
  • 55 Usuki K, Sekiyama M, Shimada T. et al. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology 2000; 200: 324-327
    CrossrefPubMedGoogle Scholar
  • 56 Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol 1999; 38: 1-11
    PubMedGoogle Scholar
  • 57 Herbst RA, Vogelbruch M, Ehnis A. et al. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol 2000; 142: 574-575
    CrossrefPubMedGoogle Scholar
  • 58 Massa AF, Vasconcelos P, Soares de Almeida L. et al. Pityriasis rubra pilaris mixed type III/IV successfully treated with narrow band-ultraviolet B. Indian J Dermatol Venereol Leprol 2015; 81: 435
    PubMedGoogle Scholar